%0 Journal Article
%T Maraviroc in Antiretroviral-Na ve HIV-1 Patients
%A Beniam Ghebremedhin
%J Infectious Diseases: Research and Treatment
%D 2012
%I 
%R 10.4137/IDRT.S7597
%X New antiretroviral agents that are better tolerated with less side effects and novel resistance patterns are needed at all lines of human immunodeficiency virus (HIV) therapeutic strategies. The CC-chemokine receptor 5 (CCR5) antagonist maraviroc is a member of the novel class of ˇ°antiretroviral agentsˇ± that prevents the entry of HIV-1 into host cells by blocking the CCR5 coreceptor. In the MERIT (Maraviroc versus Efavirenz in Treatment-Na ve Patients) study in antiretrovial-na ve patients aged ˇÝ16 years with CCR5-tropic HIV-1 infection, maraviroc showed noninferiority to efavirenz for virological endpoints. Evidences from trials suggest that maraviroc is effective at reducing HIV-1 viral load in antiretroviral-experienced and -na ve patients with CCR5-tropic virus, as well as in those with CCR5-tropic virus who have developed HIV-1 resistance to existing antiretroviral regimens. Recent in vitro study demonstrated that maraviroc was also active against CCR5-tropic HIV-2 strains.
%U http://www.la-press.com/maraviroc-in-antiretroviral-nave-hiv-1-patients-article-a2995